Navigation Links
Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
Date:9/3/2008

SAN FRANCISCO, Sept. 3 /PRNewswire/ -- Osprey Pharmaceuticals U.S.A., a privately-held company focused on developing novel protein therapeutics that selectively target chemokine-activated leukocytes that are responsible for initiating and maintaining inflammatory diseases, announced today that the company has raised $11 million in its first round of venture capital funding. The financing was led by Burrill & Company with participation from Novo Nordisk Biotech Fund (Novo Nordisk's internal corporate venture fund), Yasuda Enterprise Development, GeneChem Therapeutics Venture Fund, BDC Venture Capital, Inc. and Western Technology Seed Investment Fund.

"With a lead compound poised to enter clinical studies and a rich pipeline of highly specific protein therapeutics designed to target chemokine-mediated inflammation, we are enthusiastic about the opportunity to invest in Osprey Pharmaceuticals U.S.A.," said John E. Hamer, Ph.D., Managing Partner of Burrill & Company on behalf of the company's investors. "The company has acquired a powerful drug discovery platform which has the potential to yield new high value therapeutics against inflammatory and autoimmune disease."

Osprey Pharmaceuticals U.S.A. will deploy these funds to advance the company's lead product, a therapeutic fusion protein known as CCL2-LPM, into a safety and proof-of-concept clinical trial. CCL2-LPM is designed to target the CCL2-CCR2 chemokine ligand and receptor axis, which play a significant role in inflammatory kidney diseases and other autoimmune and inflammatory conditions. Proceeds will also be applied to the discovery and development of additional therapeutics that have emerged from the company's proprietary platform for the discovery of therapeutic Leukocyte Population Modulators (LPMs). LPMs specifically target chemokine-activated leukocytes that drive and/or maintain a variety of inflammatory and autoimmune disorders.

"We are pleased to have received strong support
'/>"/>

SOURCE Osprey Pharmaceuticals U.S.A., Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Osprey Pharmaceuticals Names Jack M. Anthony as CEO
2. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... METTLER TOLEDO recently announced that ...Optimization Using At-Line Particle Characterizati... In this webinar, the application of in situ parti...sign space and optimize a series of roller compact...and roller compaction forces. , ...
(Date:11/19/2009)...HAGEN, Nov. 19 Danish Prince Joach...sic ethanol plant in Kalundborg, Denmark, on Wedne...d,s first and largest 2nd generation ethanol demon...ymes are used in the plant,s innovative process fo...f Danisco, was the first to market with commercial...
(Date:11/19/2009)... ,, BETHESDA, Md., Nov. 19 /PRNewswire-FirstCa...nnovator in biotechnology for diabetes therapy, an...g services to food, supplement, biotechnology and ...d the previously reported $6.3 million registered ...60,870 shares of its common stock and warrants to ...
(Date:11/19/2009)...MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRNewswi...ion Resources find that the leading driver of anti... is broad-spectrum activity against gram-positive ... organisms that can cause nosocomial pneumonia, su...rimarily for agents that provide appropriate cover...
Breaking Biology Technology:Roller Compaction Process Optimization Using At-Line Particle Characterization 2DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
... scheduled for March 12, 2009 , , NEW YORK, Marc...X ) today announced that it received a letter from...hat the Company had failed to regain compliance wi...res the Company to have a minimum of $2,500,000 in... of listed securities, or $500,000 of net income f...
...roteon Therapeutics, Inc., announced today that it... equity financing, led by MPM Capital on behalf of...uncement follows the initiation of a Phase 1/2 hum... patients with end stage renal disease undergoing ...Additionally, Proteon further bolstered its cash r...
...rusted LASIK Surgeons launched its revolutionary T...e at www.TrustedLASIKSurgeons.com in order to pr...their vision and find a highly qualified surgeon w...20 vision. What sets the Trusted LASIK Surgeons d...ing that only those who are among the best in LASI...
Other Biology Technology:Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 2Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 3Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 4Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company 2Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 2Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 3Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 4Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 5Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 6Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory 7
(Date:11/19/2009)... N.J., Nov. 19 BIO-key I...eader in wireless public safety and finger-based b...the Special Shareholder Meeting held today was adj...orum was not present. ,, (Logo: http://www.new...hile an impressive 99.3% of the 35 million votes c...
(Date:11/19/2009)... State,s Ross Hardison, T. Ming Chu Professor of B...ge step toward unraveling how regulatory proteins ...elopment and growth. Working with collaborators in...ldren,s Hospital of Philadelphia, they focused spe...blood cells (erythrocytes). These cells contain la...
(Date:11/19/2009)...iversity of Cincinnati professor of paleontology i...author Michael Foote of the University of Chicago ...ience with their paper, "Epicontinental Seas Vers...ction and Origination." , For many years, paleob... biodiversity have focused on charting the many up...
Breaking Biology News(10 mins):BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3New research into the mechanisms of gene regulation 2New research into the mechanisms of gene regulation 3New research into the mechanisms of gene regulation 4New research into the mechanisms of gene regulation 5Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 2Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 3Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 4American Lung Association Launches Retro Marketing Initiative to Support 2009 Christmas Seals 28R 29 Campaign 57640 1American Lung Association Launches Retro Marketing Initiative to Support 2009 Christmas Seals 28R 29 Campaign 57640 2American Lung Association Launches Retro Marketing Initiative to Support 2009 Christmas Seals 28R 29 Campaign 57640 3Kidney Transplant at 84 Chicago Artist Proves New Start Possible at Any Age 57637 1Kidney Transplant at 84 Chicago Artist Proves New Start Possible at Any Age 57637 2Kidney Transplant at 84 Chicago Artist Proves New Start Possible at Any Age 57637 3Kidney Transplant at 84 Chicago Artist Proves New Start Possible at Any Age 57637 4MedWaves Inc Sponsors Investigational Studies to Evaluate Its Patented Microwave Thermal Coagulation Ablation System for Treatment of Tumors in Live 57634 1MedWaves Inc Sponsors Investigational Studies to Evaluate Its Patented Microwave Thermal Coagulation Ablation System for Treatment of Tumors in Live 57634 2MedWaves Inc Sponsors Investigational Studies to Evaluate Its Patented Microwave Thermal Coagulation Ablation System for Treatment of Tumors in Live 57634 3MedWaves Inc Sponsors Investigational Studies to Evaluate Its Patented Microwave Thermal Coagulation Ablation System for Treatment of Tumors in Live 57634 4
...s have developed a new prenatal blood test that ac...ous chromosomal defects in a small study of 18 pre...ay, the test would offer a safer and faster altern...esis that pose a small risk of miscarriage., Resea...od contains small amounts of DNA from the fetus. H...
...logists at Washington University in St. Louis show... area, the less chance humans have of exposure to ...e birds. , "The bottom line is that where there ar...h lower risk of contracting West Nile Fever," said...s & Sciences at Washington University in St. Louis...
...s of cells have in common with a mixture of oil an... to separate into two distinct regions. , That is...r model of the cell sorting process produced by Sh...erbilt University, and his colleagues at the Unive...he Oct. 3 issue of the journal Physical Review Le...
Other Biology News:New blood test for Down syndrome 2New blood test for Down syndrome 3New blood test for Down syndrome 4Study: Bird diversity lessens human exposure to West Nile Virus 2Surface tension drives segregation within cell mixtures 2
ARCA (Anti Reverse Cap Analog) from Ambion
TRIzol LS Reagent from Invitrogen
UltraPure DNase/RNase-Free Distilled Water from Invitrogen
Rabbit Complement from Pel-Freez Biologicals
Biology Products: